| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Target: Isotope-Labeled Compounds / HMG-CoA Reductase Pathway. Mevalonic acid is the product of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway that produces cholesterol, dolichol, ubiquinone, and isoprenoids. It is a key intermediate in sterol and isoprenoid biosynthesis. The labeled version is an analytical standard, not a pharmacological target.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a matter for concern [11].
In vitro, stable heavy isotopes of carbon and hydrogen are incorporated into drug molecules as tracers for quantitation during drug development. No specific cell-based activity is reported for the labeled form beyond its use as a tracer for metabolic flux studies in cultured cells (e.g., hepatocytes, cancer cells). |
| ln Vivo |
In vivo, the unlabeled mevalonic acid is an endogenous metabolite produced from HMG-CoA via HMG-CoA reductase. The labeled standard is used in metabolic tracer studies to investigate the mevalonate pathway in animal models after oral or IV administration. It does not exert direct pharmacological activity but is a valuable tool for studying cholesterol and isoprenoid metabolism.
|
| Enzyme Assay |
For cell-free assays: plasma, tissue homogenates, or cell lysates are spiked with Mevalonic acid-13C,d3 sodium internal standard. After protein precipitation with acetonitrile/methanol or solid-phase extraction, the samples are derivatized (if needed) and analyzed by LC-MS/MS or GC-MS. Quantitation of mevalonic acid or related metabolites (e.g., mevalonate-5-phosphate) is based on the analyte/internal standard peak area ratio. Isotope dilution mass spectrometry is used to correct for matrix effects.
|
| Cell Assay |
For cell assays: hepatocytes or other cell lines are incubated in media containing Mevalonic acid-13C,d3 sodium (typically 10-100 uM, 2-24 h) to trace mevalonate pathway flux. Cells are harvested, lipids and isoprenoids are extracted, and labeled metabolites (cholesterol, dolichol, ubiquinone, geranylgeranyl pyrophosphate) are analyzed by LC-MS/MS to quantify incorporation of the labeled tracer into downstream products, revealing pathway activity and flux rates.
|
| Animal Protocol |
For animal studies: mice or rats are administered Mevalonic acid-13C,d3 sodium via oral gavage, intraperitoneal injection, or intravenous infusion (typically 10-50 mg/kg). Serial blood samples are collected, and tissues (liver, adipose, muscle, brain) are harvested post-mortem. The labeled internal standard is used in LC-MS/MS analysis to quantify mevalonic acid and its metabolites in these samples for metabolic flux analysis and to study the effects of statins or other HMG-CoA reductase inhibitors on the mevalonate pathway.
|
| ADME/Pharmacokinetics |
PK properties of mevalonic acid: it is an endogenous intermediate with a very short half-life (<1 h). Exogenous mevalonic acid is rapidly cleared from plasma and taken up by tissues, particularly the liver, where it is phosphorylated to mevalonate-5-phosphate by mevalonate kinase. It is further metabolized to isopentenyl pyrophosphate (IPP) and then to cholesterol and other isoprenoids. Excretion occurs mainly as CO2 via respiration. The labeled standard does not alter PK.
|
| Toxicity/Toxicokinetics |
No toxicity data are available for the labeled standard. Mevalonic acid is an endogenous metabolite and is considered non-toxic at physiological levels. The labeled compound is for research use only and is not intended for human therapeutic administration. It is non-hazardous for transport under normal laboratory conditions. Not for human consumption.
|
| References | |
| Additional Infomation |
Mevalonic acid-13C,d3 sodium is a research standard, not a drug. It is not FDA-approved for clinical use. It is used in metabolic research to study the mevalonate pathway, cholesterol biosynthesis, and isoprenoid metabolism in health and disease (e.g., hypercholesterolemia, cancer, neurodegenerative diseases). It is an essential tool for investigating the mechanism of statin drugs and for developing new therapies targeting the mevalonate pathway. The labeled compound is also used in quality control for statin manufacturing.
|
| Exact Mass |
174.078
|
|---|---|
| CAS # |
2747918-57-4
|
| PubChem CID |
163322125
|
| Appearance |
Colorless to light yellow ointment
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H][13C]([2H])([2H])C(CCO)(CC(=O)[O-])O.[Na+]
|
| InChi Key |
RIYNLCMADQUBEM-SPZGMPHYSA-M
|
| InChi Code |
InChI=1S/C6H12O4.Na/c1-6(10,2-3-7)4-5(8)9;/h7,10H,2-4H2,1H3,(H,8,9);/q;+1/p-1/i1+1D3;
|
| Chemical Name |
sodium 3,5-dihydroxy-3-(trideuterio(113C)methyl)pentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
